Analysis of Reportable Segments
Boston Scientific Corp. operates in 2 segments: MedSurg and Cardiovascular.
Segment Profit Margin
Boston Scientific Corp., profit margin by reportable segment
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| MedSurg | 32.13% | 33.02% | 30.07% | — | — |
| Cardiovascular | 25.89% | 26.18% | 17.64% | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | MedSurg | MedSurg segment profit margin ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022. |
| Cardiovascular | Cardiovascular segment profit margin ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022. |
Segment Profit Margin: MedSurg
Boston Scientific Corp.; MedSurg; segment profit margin calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating income | 1,625) | 1,524) | 1,156) | —) | —) |
| Net sales | 5,057) | 4,616) | 3,844) | —) | —) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 32.13% | 33.02% | 30.07% | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment profit margin = 100 × Operating income ÷ Net sales
= 100 × 1,625 ÷ 5,057 = 32.13%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | MedSurg | MedSurg segment profit margin ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022. |
Segment Profit Margin: Cardiovascular
Boston Scientific Corp.; Cardiovascular; segment profit margin calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating income | 2,113) | 1,888) | 1,043) | —) | —) |
| Net sales | 8,161) | 7,212) | 5,913) | —) | —) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 25.89% | 26.18% | 17.64% | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment profit margin = 100 × Operating income ÷ Net sales
= 100 × 2,113 ÷ 8,161 = 25.89%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Cardiovascular | Cardiovascular segment profit margin ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022. |
Segment Return on Assets (Segment ROA)
Boston Scientific Corp., ROA by reportable segment
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| MedSurg | 64.97% | 69.97% | 58.03% | — | — |
| Cardiovascular | 40.60% | 42.74% | 26.51% | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | MedSurg | MedSurg segment ROA improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022. |
| Cardiovascular | Cardiovascular segment ROA improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022. |
Segment ROA: MedSurg
Boston Scientific Corp.; MedSurg; segment ROA calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating income | 1,625) | 1,524) | 1,156) | —) | —) |
| Total assets | 2,501) | 2,178) | 1,992) | —) | —) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 64.97% | 69.97% | 58.03% | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment ROA = 100 × Operating income ÷ Total assets
= 100 × 1,625 ÷ 2,501 = 64.97%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | MedSurg | MedSurg segment ROA improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022. |
Segment ROA: Cardiovascular
Boston Scientific Corp.; Cardiovascular; segment ROA calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating income | 2,113) | 1,888) | 1,043) | —) | —) |
| Total assets | 5,205) | 4,417) | 3,934) | —) | —) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 40.60% | 42.74% | 26.51% | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment ROA = 100 × Operating income ÷ Total assets
= 100 × 2,113 ÷ 5,205 = 40.60%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Cardiovascular | Cardiovascular segment ROA improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022. |
Segment Asset Turnover
Boston Scientific Corp., asset turnover by reportable segment
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| MedSurg | 2.02 | 2.12 | 1.93 | — | — |
| Cardiovascular | 1.57 | 1.63 | 1.50 | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | MedSurg | MedSurg segment asset turnover ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
| Cardiovascular | Cardiovascular segment asset turnover ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
Segment Asset Turnover: MedSurg
Boston Scientific Corp.; MedSurg; segment asset turnover calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Net sales | 5,057) | 4,616) | 3,844) | —) | —) |
| Total assets | 2,501) | 2,178) | 1,992) | —) | —) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 2.02 | 2.12 | 1.93 | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 5,057 ÷ 2,501 = 2.02
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | MedSurg | MedSurg segment asset turnover ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
Segment Asset Turnover: Cardiovascular
Boston Scientific Corp.; Cardiovascular; segment asset turnover calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Net sales | 8,161) | 7,212) | 5,913) | —) | —) |
| Total assets | 5,205) | 4,417) | 3,934) | —) | —) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 1.57 | 1.63 | 1.50 | — | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 8,161 ÷ 5,205 = 1.57
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Cardiovascular | Cardiovascular segment asset turnover ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
Net sales
Boston Scientific Corp., net sales by reportable segment
US$ in millions
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| MedSurg | 5,057) | 4,616) | 3,844) | —) | —) |
| Cardiovascular | 8,161) | 7,212) | 5,913) | —) | —) |
| Total reportable segments | 13,218) | 11,828) | 9,757) | —) | —) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Operating income
Boston Scientific Corp., operating income by reportable segment
US$ in millions
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| MedSurg | 1,625) | 1,524) | 1,156) | —) | —) |
| Cardiovascular | 2,113) | 1,888) | 1,043) | —) | —) |
| Total reportable segments | 3,738) | 3,412) | 2,199) | —) | —) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Total assets
Boston Scientific Corp., total assets by reportable segment
US$ in millions
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| MedSurg | 2,501) | 2,178) | 1,992) | —) | —) |
| Cardiovascular | 5,205) | 4,417) | 3,934) | —) | —) |
| Total reportable segments | 7,706) | 6,595) | 5,926) | —) | —) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).